Stoke Therapeutics, Inc. Common Stock

Ratings for Stoke Therapeutics (NASDAQ:STOK) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 3 0 0 0 0 3M Ago 1 0 0 0 0 Analysts have set 12-month price targets for Stoke Therapeutics, revealing an average target of $24.2, a high estimate of $35.00, and a low estimate of $20.00. Experiencing a 3.2% decline, the current average is now lower than the previous average price target of $25.00. Understanding Analyst Ratings: A Comprehensive Breakdown A clear picture of Stoke Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Joseph Stringer Needham Maintains Buy $22.00 $22.00 Andrew Fein HC Wainwright & Co. Maintains Buy $35.00 $35.00 Sumant Kulkarni Canaccord Genuity Lowers Buy $20.00 $21.00 Joseph Stringer Needham Maintains Buy $22.00 $22.00 Joseph Stringer Needham Maintains Buy $22.00 - Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their ...Full story available on Benzinga.com

Related tickers: STOK.

Stoke Therapeutics (NASDAQ:STOK) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 1 1 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 3 1 1 0 0 3M Ago 1 0 0 0 0 Analysts have recently evaluated Stoke Therapeutics and provided 12-month price targets. The average target is $20.75, accompanied by a high estimate of $35.00 and a low estimate of $13.00. Witnessing a positive shift, the current average has risen by 62.75% from the previous average price target of $12.75. Understanding Analyst Ratings: A Comprehensive Breakdown A comprehensive examination of how financial experts perceive Stoke Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Joseph Stringer Needham Maintains Buy $22.00 - Joseph Stringer Needham Maintains Buy $22.00 - Laura Chico Wedbush Raises Outperform $17.00 $13.00 Sumant Kulkarni Canaccord Genuity Raises Buy $21.00 $18.00 Jessica Fye JP Morgan Raises Neutral $13.00 $6.00 Andrew Fein HC Wainwright & Co. Maintains Buy $35.00 - Joseph Stringer Needham Raises Buy $22.00 $14.00 Joseph Stringer Needham Maintains Buy $14.00 - Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Stoke Therapeutics. This information ...Full story available on Benzinga.com

Related tickers: STOK.